Literature DB >> 1602138

Apoptosis is induced in cells with cytolytic potential by L-leucyl-L-leucine methyl ester.

D L Thiele1, P E Lipsky.   

Abstract

Previous studies have demonstrated that the selective toxicity of leucyl-leucine methyl ester (Leu-Leu-OMe) for cytotoxic lymphocytes and myeloid cells is dependent on intracellular conversion to membranolytic metabolites by the acyl transferase activity of the granule enzyme dipeptidyl peptidase I (DPPI) that is enriched in these cells. The mechanism of cell death remained unclear, however, and was the subject of the experiments reported here. When human U937, HL60, or THP-1 myeloid tumor cell lines or murine CTLL-2 cells were treated with Leu-Leu-OMe, early release of both cytosolic 51Cr and soluble [3H]TdR labeled DNA fragments was observed, whereas antibody + C treatment of these cells caused only 51Cr release. Killing of U937 or THP-1 cells by incubation with the lysosomotropic amino acid methyl ester, Phe-OMe also induced only 51Cr release without evidence of DNA fragmentation. Preincubation with Zn2+, a known inhibitor of endonuclease activity prevented Leu-Leu-OMe-induced 51Cr or [3H]TdR release from these cell lines, but had no effect on antibody + C or Phe-OMe-induced 51Cr release. Zn2+ also prevented Leu-Leu-OMe-mediated killing of normal human CD16+ NK cells. Zn2+ had no inhibitory effect on Leu-Leu-OMe uptake or intracellular conversion to (Leu-Leu)n-OMe metabolites by these cell lines. Moreover, Zn2+ did not inhibit 51Cr release from nonnucleated E or nucleated U937 targets induced by extracellular production of DPPI-generated metabolites of Leu-Leu-OMe. Thus, killing of cytotoxic lymphocytes and myeloid cells by Leu-Leu-OMe appears to be dependent on generation of metabolites with membranolytic properties, but cell death induced by this process does not involve simple lysis of the plasma membrane. Rather, intracellular production of DPPI generated (Leu-Leu)n-OMe metabolites appears to trigger, an additional Zn(2+)-sensitive process that is associated with induction of apoptosis in cells with cytolytic potential.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1602138

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Glial connexins and gap junctions in CNS inflammation and disease.

Authors:  Tammy Kielian
Journal:  J Neurochem       Date:  2008-04-10       Impact factor: 5.372

2.  Cathepsin-mediated necrosis controls the adaptive immune response by Th2 (T helper type 2)-associated adjuvants.

Authors:  Lee S Jacobson; Heriberto Lima; Michael F Goldberg; Vasilena Gocheva; Vladislav Tsiperson; Fayyaz S Sutterwala; Johanna A Joyce; Bianca V Gapp; Vincent A Blomen; Kartik Chandran; Thijn R Brummelkamp; Felipe Diaz-Griffero; Jürgen Brojatsch
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

3.  T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.

Authors:  Thea M Friedman; Joanne Filicko-O'Hara; Bijoyesh Mookerjee; John L Wagner; Delores A Grosso; Neal Flomenberg; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2007-12       Impact factor: 5.742

4.  Resistance to apoptosis in CTLL-2 cells constitutively expressing c-Myb is associated with induction of BCL-2 expression and Myb-dependent regulation of bcl-2 promoter activity.

Authors:  P Salomoni; D Perrotti; R Martinez; C Franceschi; B Calabretta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Apoptosis induced by (di-isopropyloxyphoryl-Trp)2-Lys-OCH3 in K562 and HeLa cells.

Authors:  Feng Liu; Shi-Ying Liu; Ping Xu; Zheng-Hua Xie; Guo-Ping Cai; Yu-Yang Jiang
Journal:  J Biosci       Date:  2008-03       Impact factor: 1.826

6.  Lysosomal membrane permeabilization causes secretion of IL-1β in human vascular smooth muscle cells.

Authors:  Hiroaki Ono; Ryo Ohta; Yuri Kawasaki; Akira Niwa; Hidetoshi Takada; Tatsutoshi Nakahata; Shouichi Ohga; Megumu K Saito
Journal:  Inflamm Res       Date:  2018-08-22       Impact factor: 4.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.